Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

168 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and efficacy of nab-paclitaxel (Abraxane) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

NCT02501902

Metastatic Pancreatic Ductal Adenocarcinoma

COMPLETED PHASE1

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

NCT02301143

Pancreatic Neoplasms

COMPLETED PHASE2

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

NCT02506842

Stage ⅠA Pancreatic Cancer Stage ⅠB Pancreatic Cancer Stage ⅡA Pancreatic Cancer +1 more

UNKNOWN PHASE3

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

NCT01161186

Pancreatic Neoplasms Pancreatic Cancer Adenocarcinoma

COMPLETED PHASE1

Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer

NCT02382263

Advanced Pancreatic Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Pancreatic Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AG

nab-Paclitaxel followed by Gemcitabine

Group Type ACTIVE_COMPARATOR

nab-paclitaxel

Intervention Type DRUG

Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes

gemcitabine

Intervention Type DRUG

Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes

AG-mFOLFOX

nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial

Group Type EXPERIMENTAL

m-FOLFOX

Intervention Type DRUG

Day 28 according to the dose levels stablished in Phase I

nab-paclitaxel

Intervention Type DRUG

Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I

gemcitabine

Intervention Type DRUG

Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nab-paclitaxel

Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes

Intervention Type DRUG

gemcitabine

Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes

Intervention Type DRUG

m-FOLFOX

Day 28 according to the dose levels stablished in Phase I

Intervention Type DRUG

nab-paclitaxel

Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I

Intervention Type DRUG

gemcitabine

Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically and/or cytologically confirmed pancreatic adenocarcinoma
2. Stage IV disease (metastatic only)
3. No prior systemic therapy for their diagnosis (except in adjuvant/neoadjuvant setting\>six months previously)
4. ECOG performance status of 0-1
5. At least 18 years of age
6. Evidence of either or both of the following RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter ≥ 20mm using conventional techniques or ≥10 mm with spiral CT scan)
7. Female patients must be either surgically sterile or postmenopausal, or if of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment and agree to use effective barrier contraception during the period of therapy. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the investigator.
8. Adequate bone marrow function:

* ANC ≥ 1500/uL
* platelet count ≥ 100,000/uL
* hemoglobin ≥ 9.0 g/dL
9. Adequate hepatic function:

* Total bilirubin ≤ 1.5 X ULN
* AST (SGOT) ≤ 2.5 X ULN
* ALT (SGPT) ≤ 2.5 X ULN
10. Adequate renal function as determined by either:

\- Calculated or measured creatinine clearance ≥ 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used).
11. Ability to understand the nature of this study protocol and give written informed consent.
12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria

1. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study.
2. Presence of central nervous system or brain metastases.
3. Life expectancy \< 12 weeks
4. Pregnancy (positive pregnancy test) or lactation.
5. Pre-existing sensory neuropathy \> grade 1.
6. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
7. Major surgery and/or radiotherapy within 4 weeks of the start of study treatment, without complete recovery.
8. Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No